Atenativ for people with inherited low antithrombin during surgery or birth
Part of Blood & lymphatic, Genetic & congenital, Women’s health & pregnancy clinical trials.
This trial tests whether Atenativ (an antithrombin treatment) lowers dangerous blood clots during planned surgery or during late pregnancy/delivery. It’s for people with a rare inherited blood-clotting condition called congenital antithrombin deficiency.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 80 years old
- Have confirmed congenital antithrombin deficiency (antithrombin activity ≤ 60% on past tests)
- Have had blood clots (TE) or related serious clot events (TEEs) in your past, or in close family
- Have a planned study treatment event: scheduled high-risk surgery, or a planned C-section/delivery at 27+ weeks (if pregnant)
- For people who can get pregnant: have a negative urine pregnancy test at screening and before starting
- Be able to give informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at patient records to see how antithrombin (a medicine that helps prevent blood clots) was used in intensive care or during surgery. It does not test a new treatment, but helps doctors understand if the medicine was given appropriately.
This Phase 2 trial studies whether giving antithrombin can better prevent harmful blood clots (venous thromboembolism) after serious injuries. The goal is to reduce clot risk while you’re in the trauma ICU or step-down unit.
This study tests a blood-derived medicine (antithrombin) to help people who do not respond well to the blood thinner heparin during heart surgery. It aims to make surgery safer by improving blood thinning.
This study is a registry that collects information about people with antithrombin deficiency, a rare blood disorder that increases the risk of blood clots. By joining, you help doctors learn more about the condition and improve care for others.
This study tests a new medicine called TGD001 for people with a group of rare blood disorders called thrombotic microangiopathies (TMAs), where small blood clots form and damage organs. The goal is to see if TGD001 can help stop the clotting and improve outcomes.
This study tests personalized blood thinner treatments for people with blood clots in their lungs. It looks for patients who are older, have kidney problems, or have cancer, to see if adjusting the treatment helps them more.
Hear when a new Congenital Antithrombin Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.